CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION
Rhea-AI Summary
Catheter Precision (NYSE:VTAK) reported Q1 2026 revenue of $432,000, up 200% year-over-year from $143,000, driven by its medical device business and newly acquired Flyte aviation platform.
Net loss improved to $1.7 million from $4.0 million as Flyte rapidly scaled and medical devices expanded globally.
AI-generated analysis. Not financial advice.
Positive
- Q1 2026 revenue up 200% YoY to $432,000
- Medical device segment revenue increased approximately 73%
- Products now utilized in 15 countries worldwide
- Flyte fleet expanded from 1 to 3 aircraft, 2 more expected by Q2 2026 end
- Flyte reached $200,000 monthly revenue run rate within 22 days
- Net loss reduced to $1.7 million from $4.0 million YoY
Negative
- Company still reports a net loss of $1.7 million for Q1 2026
- Net loss includes about $560,000 in non-cash expenses
News Market Reaction – VTAK
On the day this news was published, VTAK gained 9.07%, reflecting a notable positive market reaction. Argus tracked a peak move of +25.0% during that session. Argus tracked a trough of -11.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $186K to the company's valuation, bringing the market cap to $2.23M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VTAK was down 1.4% while momentum-screened peers like AEMD and BJDX showed upside moves, and broader medical device peers were mixed. This points to stock-specific dynamics rather than a sector-wide move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 16 | Flyte acquisition closed | Positive | -13.2% | Completion of shareholder-approved acquisition of Flyte and full consolidation. |
| Mar 10 | Flyte merger deal | Positive | +25.6% | Definitive merger agreement to acquire remaining Flyte equity interest. |
| May 06 | Cardionomic assets buy | Positive | -1.2% | Acquisition of CPNS heart failure assets targeting large ADHF market. |
| Apr 23 | CPNS deal agreement | Positive | +4.6% | Definitive agreement to acquire CPNS System heart failure assets. |
| Feb 04 | PeriKard acquisition | Positive | -2.6% | Closing of all-stock PeriKard acquisition aligned with VT market focus. |
Acquisition announcements have generally been framed positively but produced mixed reactions, with 3 negative and 2 positive next-day moves, indicating inconsistent market confidence around deal execution and financing.
Over the past year, VTAK has repeatedly used acquisitions to reshape its profile. Earlier deals added PeriKard and Cardionomic heart failure assets, while recent transactions secured 100% ownership of Flyte, an FAA Part 135 regional aviation platform. Price reactions to these M&A steps have been mixed, including a -13.18% move on April 16, 2026, and a 25.55% move on March 10, 2026. Today’s update ties those strategic moves to Q1 2026 revenue growth and loss reduction, highlighting initial integration impact.
Historical Comparison
Compared with prior acquisition headlines that drew mixed one-day moves averaging 2.63%, this update emphasizes early revenue and loss impacts from the Flyte deal rather than just transactional terms.
Acquisition strategy has evolved from ventricular-focused assets (PeriKard, Cardionomic CPNS) toward a dual-platform model, culminating in full ownership of Flyte to add an aviation revenue engine alongside cardiac devices.
Market Pulse Summary
The stock moved +9.1% in the session following this news. A strong positive reaction aligns with the headline Q1 revenue growth of 200% to $432,000 and a net loss improvement to $1.7 million. Historically, acquisition updates have produced mixed moves, so sustained strength would depend on confidence in integrating Flyte and funding expansion. Recent filings highlight tight liquidity, going-concern language, and use of preferred stock financings, which could temper enthusiasm if investors refocus on dilution and balance-sheet risk.
Key Terms
electrophysiology medical
ventricular tachyarrhythmia medical
ventricular tachycardia medical
part 135 regulatory
AI-generated analysis. Not financial advice.
Medical Device Momentum Accelerates Globally While Flyte Establishes High-Growth Aviation Platform with Immediate Revenue Traction
Dramatic Reduction in Net Loss and Expanding Multi-Segment Growth Position Company for Scalable, High-Impact Expansion
FORT MILL, S.C., May 18, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (“Catheter Precision” or the “Company”), an innovative U.S.-based medical device and technology company, today reported financial results for the first quarter of 2026, highlighting strong revenue growth, meaningful margin improvement, and the successful acquisition and rapid scaling of Flyte.
First quarter revenue grew
MEDICAL DEVICE SEGMENT DELIVERS STRONG GLOBAL EXPANSION AND CLINICAL VALIDATION
The Company’s electrophysiology platform continues to gain traction with physicians and institutions globally, supported by clinical validation, peer-reviewed research, and expanding adoption.
Key Highlights:
- Revenue increased approximately
73% , driven by new customer acquisition across the United States and Europe - Adoption of both VIVO and LockeT expanded across multiple new institutions
- Products are now utilized in 15 countries worldwide, underscoring growing global demand
- New clinical publications validated both technologies, including:
- LockeT demonstrating expanded large bore applications
- VIVO demonstrating high accuracy across 32 patients and 46 ventricular tachyarrhythmia sites, reinforcing its value in VT therapy procedures
- Presented breakthrough research at the Heart Rhythm Society Congress, including first-in-human data leveraging implantable device EGM data to predict ventricular tachycardia origin
- Continued expansion into new hospitals across the U.S. and Europe, further accelerating commercial penetration
FLYTE ACQUISITION IGNITES HIGH-GROWTH AVIATION PLATFORM WITH IMMEDIATE REVENUE AND SCALABILITY
The acquisition of Flyte marks a transformative step into technology-enabled regional air mobility, delivering immediate revenue contribution and significant growth visibility.
Flyte Segment Highlights:
- Fleet scaled from 1 aircraft at acquisition to 3 aircraft, with 2 additional jets expected by the end of Q2 2026
- Generated a
$200,000 m onthly revenue run rate within just 22 days of post-acquisition operations in March - Deployment of AI-driven booking and optimization technology to increase utilization and drive operational efficiency
- Positioned to capitalize on high-demand Northeast summer travel, including routes to:
- The Hamptons
- Martha’s Vineyard
- Cape Cod
- Filed applications with the Federal Aviation Administration to expand service into international markets including Toronto and the Bahamas
Flyte operates through its FAA-certified Part 135 carrier, establishing a scalable, asset-backed aviation infrastructure platform targeting underserved short-haul markets with high-frequency demand.
FINANCIAL PERFORMANCE
- Net loss reduced to
$1.7 million , compared to$4.0 million in Q1 2025 - Represents a substantial year-over-year improvement, driven by revenue growth and operating discipline
- Net loss includes approximately
$560,000 of depreciation, amortization, and stock-based compensation non-cash expenses. - Continued focus on improving operating leverage as revenue scales across both segments
STRATEGIC POSITIONING
Catheter Precision is now uniquely positioned as a dual-engine growth platform, combining:
- High-margin, clinically validated medical device innovation
- Rapidly scaling, technology-enabled aviation infrastructure
This differentiated model provides multiple pathways to growth, diversified revenue streams, and the ability to capture value across both healthcare and mobility markets.
ABOUT LOCKET
LockeT is a Class I FDA-registered suture retention device designed to assist in wound closure following percutaneous venous procedures, improving efficiency and patient outcomes.
ABOUT VIVO
VIVO (View Into Ventricular Onset) is a non-invasive 3D cardiac imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, improving workflow efficiency and reducing procedure time. VIVO has received U.S. FDA clearance and CE Mark certification.
ABOUT CATHETER PRECISION
Catheter Precision is a U.S.-based medical device company focused on advancing the treatment of cardiac arrhythmias through innovative electrophysiology technologies and physician collaboration.
ABOUT FLYTE
Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel. Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets. For more information, visit www.flyte.travel
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding our anticipation HRS 2026 will be a symposium where we not only demonstrate our products to new and existing customers, but where we can share new and exciting research, like the new peer-reviewed publications, that validate our products to the EP community. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contacts:
Investor Relations
973-691-2000
IR@catheterprecision.com
